List view / Grid view
Scientists have grown the first multi-regional “mini-stomach” in the lab, creating a new way to study rare genetic stomach diseases and help to develop new treatments for digestive conditions.
Researchers have identified new drug candidates that selectively target the cPLA2 enzyme, a key driver of brain inflammation linked to Alzheimer’s disease, offering a potential new approach to reducing risk in people with the APOE4 gene.
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
Researchers have discovered how seemingly supportive brain cells help glioblastoma thrive, whilst identifying an existing HIV drug, Maraviroc, that could be repurposed to slow tumour growth.
New research has revealed how cellular senescence – the process in which ageing cells change function – shapes human brain structure from development to old age, improving our understanding of brain ageing and neurodegenerative diseases.
Researchers have developed vascularised human retinal organoids featuring the first fully functional light-signal pathways in lab-grown human retina models, opening new possibilities for studying eye disease and testing therapies.
Researchers have shown that applying magnetic forces to lab-grown human heart organoids enhances their maturation and vascular development, offering a more realistic model of early heart formation and the possibility of future cardiac therapies.
Researchers have engineered new extracellular vesicles that can selectively induce antigen-specific regulatory T cells, possibly leading towards safer, more precise treatments for autoimmune and allergic diseases.
Kobe University researchers have developed a new way of freeze induced pluripotent stem cells (iPS cells) directly in their culture dishes without losing viability or pluripotency.
A partnership between Atelerix and Cherry Biotech is enabling the shipping of complex biological models worldwide, using hydrogel preservation technology to eliminate cold-chain logistics.
New research suggests cannabis compounds CBD and THC could offer a new approach to treating ovarian cancer.
Researchers at NYU Abu Dhabi have developed a cheap, paper-based platform that allows tumour models to be grown, frozen and stored for future cancer drug testing – called Spheromatrix.
Scientists have developed an organ-on-a-chip platform that replicates age-related immune decline, offering a long-missing tool for testing cancer vaccines in older adults.
A preclinical study led by VHIO reveals that the MYC inhibitor Omomyc enhances the effectiveness of PARP inhibitors, offering a potential new treatment strategy for patients with drug-resistant triple-negative breast cancer.
Researchers in Japan have identified a promising blood-based marker that could enable faster, simpler and more accurate detection of liver fibrosis.
